v3.26.1
Segment Information - Schedule of Segment Net Loss and Reconciliations of Segment Operating Loss to Loss Before Income Tax Benefit (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Revenue $ 6,472 $ 14,745
Significant segment expenses    
Loss from operations 128,505 191,368
Other non-operating income (loss), net 6,397 (11,277)
Income tax benefit 4,604 158
Total segment loss 117,504 202,487
Reportable Segment    
Segment Reporting Information [Line Items]    
Revenue 6,472 14,745
Significant segment expenses    
Salaries 74,298 83,554
Consumables 7,146 54,677
Platform 7,614 8,765
Discovery 6,332 6,287
Clinical development 6,569 10,564
Depreciation and amortization 19,673 19,331
Other segment items 13,345 22,935
Loss from operations 128,505 191,368
Other non-operating income (loss), net 6,397 (11,277)
Income tax benefit 4,604 158
Total segment loss 117,504 202,487
Supplemental asset information    
Total expenditures for additions to long-lived assets $ 258 $ 2,978